Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Long-Term Evaluation of Lidoflazine in Angina Pectoris Based on Exercise Tolerance

      ,

      Cardiology

      S. Karger AG

      Exercise tolerance, Heart rate, Lidoflazine, Angina pectoris, Cycloergometric test, Double-blind test

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          32 patients with angina pectoris were treated with lidoflazine for 4.1-12.8 months. During this open study 24 of them showed definite alleviation of angina and a higher exercise tolerance. These 24 patients then entered a placebo- controlled double-blind study for up to 14.5 months, and t hereafter 22 were returned to lidoflazine therapy for up to 9.3 months. Exercise tolerance increased progressively during lidoflazine therapy, receded to pretrial levels during placebo treatment and, after re-institution of lidoflazine, returned to the levels previously attained under lidoflazine. Resting and exercising heart rate decreased on lidoflazine and increased when placebo was administered. These effects paralleled the subjective improvement and deterioration.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1972
          1972
          29 October 2008
          : 57
          : 3
          : 135-149
          Affiliations
          Division of Cardiology and the Heart Center, University Clinic, St. Rafaël, Leuven
          Article
          169512 Cardiology 1972;57:135–149
          10.1159/000169512
          4557527
          © 1972 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 15
          Categories
          Other Contribution

          Comments

          Comment on this article